Lymphoma, Extranodal NK-T-Cell Clinical Trial
Official title:
Phase II Study of MESA Chemotherapy in Patients With Natural Killer/T Cell Lymphoma
Study on the efficacy and safety of MESA chemotherapy for treating NK/T cell lymphoma
Extranodal natural killer (NK)/T-cell lymphoma (ENKTL), nasal type, is a distinct and heterogeneous histopathologic subtype of non-Hodgkin lymphoma (NHL), accounting for 5%~10%. The frequency of ENKTL among NHL patients is significantly higher in Asia than in Western countries. Despite radiotherapy and chemotherapy, the prognosis for ENKTL patients is poor, with 5-year median survival time for primary nasal site was 5 years, for non-nasal extranodal sites 6 months. ENKTL is so aggressive and has high mortality rate and till now there is no standard therapy. In recent years SMILE chemotherapy has clinical efficacy and is one of first line therapy for ENKTL. However it is apparent that this regimen is extremely toxic with grade 4 neutropenia especially for Asian patients. On these grounds, new therapy MESA is used for Asian patients with ENKTL in order to achieve good efficacy and safety. ;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT02878278 -
Differences Between Chidamide Taken Daily and Twice a Week in Therapeutic Effect,Pharmacokinetics, Pharmacodynamics and EB Virus Activation
|
Phase 2 | |
Terminated |
NCT01948180 -
Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma
|
Phase 2 | |
Completed |
NCT00069238 -
Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas
|
Phase 2 | |
Recruiting |
NCT03646422 -
AEDV Registry of Primary Cutaneous Lymphoma
|
||
Terminated |
NCT02359162 -
Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK/T-cell Lymphoma With Early Stage
|
Phase 3 | |
Recruiting |
NCT02080234 -
Combine GELOX With Concurrent Radiation Therapy for Patients With Stage IE/IIE ENKTL
|
Phase 2 | |
Completed |
NCT03049449 -
T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas
|
Phase 1 | |
Not yet recruiting |
NCT03051542 -
Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Natural Killer/T-cell Lymphoma
|
N/A | |
Not yet recruiting |
NCT03051555 -
18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Natural Killer/T-cell Lymphoma
|
N/A | |
Recruiting |
NCT03154918 -
GLIDE Regimen Followed by ASCT for Aggressive NK/T Cell Lymphoma
|
Phase 2 | |
Terminated |
NCT02533323 -
P-Gemox Regimen as First-line Chemotherapy in NK/T Lymphoma Patiens
|
Phase 2 | |
Active, not recruiting |
NCT03439501 -
Avelumab in Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma[AVENT STUDY]
|
Phase 2 | |
Recruiting |
NCT04417166 -
Pembrolizumab and Radiotherapy for Patients With NK/T Cell Lymphoma
|
Phase 2 | |
Recruiting |
NCT02859402 -
Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas
|
Phase 2 |